Sorafenib

Abstract

Stevens-johnson syndrome: case report A 34-year-old woman developed Stevens-johnson syndrome (SJS) during treatment with sorafenib for hepatocellular carcinoma. The woman, who had hepatocellular carcinoma complicating hepatitis B, started receiving treatment with sorafenib [dosage and route not stated]. Ten days after the initiation of sorafenib, she presented with erythematous itchy rash. Dermatological examination revealed erythematous target lesion, purpuric lesions and blisters and urticarial plaques extended on the back side of both feet, buccal and genital mucosa. She was admitted, laboratory tests revealed hepatic cytolysis and hypereosinophilia. Histopathologic of the biopsied sample of skin showed focal spongiosis, parakeratosis and perivascular inflammation. Based on biological, clinical and histopathologic findings, she was diagnosed with SJS. The woman’s sorafenib treatment was stopped. She was treated symptomatically, following which good biological and clinical outcome was observed.